What are the clinical consequences of reduced binding of LMWH to plasma proteins and cells?
The clinical consequences of reduced binding of LMWH to plasma proteins and cells include more predictable anticoagulant response, clearance through renal mechanism which permits once-daily administration, reduced formation of HIT antibodies, reduced activation of osteoclasts and reduced incidence of heparin-induced thrombocytopenia (HIT). These clinical consequences are beneficial to patients as they reduce the risk of recurrent thrombosis or bleeding complications and lower the risk of osteopenia. 